MTOR and acute lymphoblastic leukemia: Data from primary cells analysis from n = 20 presentation samples of DS-ALL for the RAS/MAPK, PI3K/mTOR, and JAK/STAT pathway activity profiles using WB (Supplementary Figs. S5A and S5B), as well as ELISA for activated RAS-pull-down (Fig. 4c) were integrated with the similar data we obtained using n = 7 DS-ALL relapse and n = 4 DS-ALL remission samples, as well as n = 4 non-DS ALL presentation samples and n = 2 non-DS relapse samples.